# Molecular Pharmacology Shared Resource

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2022 · $1

## Abstract

MOLECULAR PHARMACOLOGY SHARED RESOURCE (MPSR)
PROJECT SUMMARY/ABSTRACT
The Molecular Pharmacology Shared Resource (MPSR) at the UC Davis Comprehensive Cancer Center
(UCDCCC) has centralized services to conduct clinical pharmacokinetic (PK)/pharmacodynamic (PD) studies
and preclinical modeling of new therapeutics. Understanding PK/PD properties of individual drugs is essential
for preclinical and clinical drug development, as well as clinical practice of precision medicine in cancer. Many
clinical studies conducted at the UCDCCC, including investigator-initiated clinical trials (IIT) or National Cancer
Institute (NCI)-funded Experimental Therapeutics Clinical Trials Network (ETCTN) trails, and the National
Clinical Trials Network (NCTN) trials for which UCDCCC is a Lead Academic Participating Site, involve the
assessment of PK/PD properties and on-target pharmacological actions. Meanwhile, defining drug metabolism
(DM) and PK/PD characteristics in appropriate preclinical models is vital before translating new therapeutic
drugs into clinical investigations. The MPSR provides comprehensive services for high-quality collection,
processing and analysis of clinical specimens from trial patients to assess clinical PK/PD, and preclinical
assessment of novel therapeutics and regimens, including DM/PK/PD, on-target mechanisms, biomarkers,
drug-drug interactions (DDI) and combination effects. In addition, the MPSR provides support for IITs by
helping with protocol and assay development. Very recent acquisition of a state-of-the-art, live-cell metabolic
assay platform, the Seahorse XFe Analyzer, will further strengthen basic and translational research in the
areas of cancer metabolism at UCDCCC. Oversight and management of the MPSR is provided by the Director,
Aiming Yu, PhD, a world leader in the fields of DM/PK, studying molecular mechanisms of DM/PK/PD and
anticancer pharmacology, and the Technical Manager, Anthony Martinez, BS, the Assistant Director of the
Office of Clinical Research (OCR), with over 7 years' experience in clinical trials and 20 years' in cancer
research. The Specific Aims for the MPSR are: 1) Clinical Trial Specimen Management, in which the MPSR
oversees biospecimens collection, processing and storage for patients enrolled on clinical trials conducted
at UCDCCC; 2) Protocol Development and Clinical PK/PD studies, in which the MPSR supports study design,
and protocol development, develops new in-house assays and conducts targeted analyses of drugs,
metabolites and biomarkers, performs PK/PD data analysis and interpretation; and 3) Preclinical Modeling in
which the MPSR evaluates new agents and treatments for precision medicine that are translatable to the
clinic.

## Key facts

- **NIH application ID:** 10492617
- **Project number:** 5P30CA093373-20
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** Aiming Yu
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1
- **Award type:** 5
- **Project period:** 2002-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10492617

## Citation

> US National Institutes of Health, RePORTER application 10492617, Molecular Pharmacology Shared Resource (5P30CA093373-20). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10492617. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*